Abstract: Disclosed are compositions for stabilizing a source of active halogen in aqueous solution. The compositions comprise (i) at least one substituted N-hydrogen compound, such as 5,5-dimethylhydantoin, and (ii) at least one additional nitrogen compound selected from ammonia, ammonium salts, and nitrogen compounds containing no carbon-hydrogen bonds, the molar ratio of (i) and (ii) being in the range of 50:1 to 0.02:1. Active halogen-containing aqueous solutions stabilized by the above compositions are particularly useful for controlling microbial and planktonic growth in aqueous systems such as process liquids in the pulping or papermaking industry. The compositions are also useful in reducing the corrosivity of halogen-containing solutions.

Abstract: An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.

Abstract: The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: Aqueous emulsions of organopolysiloxanes functionalized with a limited amount of aminoalkyl-functional end groups and silicone resins are storage stable, yet capable of adequate crosslinking upon application to substances to be hydrophobicized.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerized into beads.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.

Abstract: The present invention provides a trialkoxysilanes having structure I wherein R1 and R2 are independently at each occurrence a C1-C3 alkyl group; R3 is independently at each occurrence a hydrogen or a C1-C3 alkyl group; R4 is a C1-C5 aliphatic radical, a C7-C12 aromatic radical, or a C5-C10 cycloaliphatic group; n is 0, 1, 2 or 3; q is 1, 2 or 3; and X? represents a charge balancing counterion. The trialkoxysilanes are useful for the preparation of nanoparticulate diagnostic imaging agent compositions.

Abstract: The present invention relates to the use of at least one piperidine ester derivative of formula (I) below: in which: R1 is a linear or branched C1-C12 alkyl radical, R2 is a linear or branched C1-C20 alkyl radical, with the proviso that the sum of the carbon atoms for R1 and R2 is between 2 and 22, in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one lipophilic active agent, and containing no dibenzoylmethane-type UV screening agent, as a solvent for said active agent in said liquid fatty phase and/or as an agent improving the solubility of said active agent in said fatty phase. The present invention also relates to a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase, characterized in that it comprises at least one piperidine ester derivative of formula (I) as defined above and in that it does not contain a dibenzoylmethane-type UV screening agent.

Abstract: The invention relates to novel modulators of the cold menthol receptor TRPM8, to a method for modulating the TRPM8 receptor using said modulators; to the use of the modulators for induction of cold sensation; and to objects and means produced using said modulators.

Abstract: A hydroxytyrosol polymer formed by either C—C coupling or C—O—C coupling is provided. Preferred polymers are formed by C—C coupling and the dimer has the following structure: Compounds of the invention have been found to have antioxidant properties and their use in antioxidant compositions forms a further aspect of the invention.

Abstract: A device includes a sensor configured to determine a condition associated with a nucleus pulposus, a reservoir configured to include a first agent capable of affecting the condition associated with the nucleus pulposus, a control element configured to provide access to the reservoir, and a controller in communication with the sensor and the control element. The controller is configured to manipulate the control element to provide access to the reservoir in response to the condition determined by the sensor.

Abstract: A device includes a first reservoir configured to include a degradation agent, a second reservoir configured to include an osteogenerative agent, and a controller configured to selectively initiate access to the first reservoir or the second reservoir.

Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.

Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.